The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines.
Who We Are
Parabilis is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable.
Our team
The potential impact of our approach has attracted a passionate team of talented individuals and advisors who are recognized leaders across clinical development, data science, biology, peptide chemistry, and business execution. We are also proud to have the backing of a robust group of blue-chip life sciences investors.
- Leadership
- Board
